# Cancer Immunology and Immunotherapy Program

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2024 · $183,261

## Abstract

Cancer Immunology and Immunotherapy Program: Summary/Abstract
The overarching scientific goal of the Cancer Immunology and Immunotherapy Program (CII) is to advance the
understanding of the interplay between the immune system and cancer to discover new strategies for immune-
based immunotherapies and to mitigate therapeutic resistance. Overall, CII Program research has led to
advances in the understanding of the molecular basis for immune cell recognition of tumors, evasive
mechanisms evolved by tumors to escape immune surveillance, how the microenvironment influences the
immune response to cancer, and technological advances in genetic engineering of T cells for adoptive cell
therapies. The CII Program is a new program since the prior competing renewal. The HDFCCC-wide
realignment of research programs enhances opportunities for direct interaction between discovery scientists
and clinical investigators within the CII Program and between programs. Research strengths of members
include expertise in immunology, immunotherapy, the tumor microenvironment, cellular therapy, and immune
therapeutic resistance. The CII Program provides a unique opportunity to address issues related to disparities
in the catchment area in leukemia, multiple myeloma, lymphoma, melanoma, and lung cancer, with special
attention placed on understanding differences in the overall clinical responses as well as access to novel
immunotherapies in this diverse population. CII members are therefore positioned to translate HDFCCC
discovery science into the clinic, and to bring clinical observations back to HDFCCC laboratories. Specifically,
CII members conduct research to (1) define the mechanistic interplay between cancer and the immune system,
(2) advance therapeutic interventions to improve outcomes with cancer immunotherapy, and (3) identify
mechanisms of resistance to cancer immunotherapy.

## Key facts

- **NIH application ID:** 10932199
- **Project number:** 5P30CA082103-25
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Lawrence Fong
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $183,261
- **Award type:** 5
- **Project period:** 1999-08-05 → 2028-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10932199

## Citation

> US National Institutes of Health, RePORTER application 10932199, Cancer Immunology and Immunotherapy Program (5P30CA082103-25). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10932199. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*